ZBD(SH:603567) news flash·2025-04-29 12:27Core Viewpoint - Zhenbaodao (603567.SH) reported a net profit of 438 million yuan for 2024, with a 20.23% year-on-year growth in pharmaceutical industrial revenue, attributed to enhanced marketing channel reforms and improved product competitiveness [1]. Group 1: Financial Performance - The company achieved a total revenue of 2.704 billion yuan for the year [1]. - The net profit attributable to shareholders reached 438 million yuan [1]. - The pharmaceutical industrial revenue grew by 20.23% compared to the previous year [1]. Group 2: Business Development - The company has made significant progress in its marketing channel reforms, leading to increased market coverage and product competitiveness [1]. - The traditional Chinese medicine sector showed steady progress, with the "Shennongzhou" e-commerce platform complementing offline markets [1]. - New drug research and product sales are advancing smoothly, with clinical trial approvals for innovative traditional Chinese medicine and multiple quality generic drugs [1]. Group 3: Strategic Initiatives - The company has implemented a refined招商模式 (refined recruitment model) to achieve extensive market coverage [1]. - The strategy focuses on driving product volume growth at the terminal level [1].